Analyses of haptoglobin level in the cerebrospinal fluid and serum of patients with neuromyelitis optica and multiple sclerosis

Clinica Chimica Acta

Volumn 417, Issue , 2013, Pages 26-30

  Chang, Kuo Hsuan ^a   Tseng, Mu Yun ^a   Ro, Long Sun ^a   Lyu, Rong Kuo ^a   Tai, Yu Han ^a   Chang, Hong Shiu ^a   Wu, Yih Ru ^a   Huang, Chin Chang ^a   Hsu, Wen Chuin ^a   Kuo, Hung Chou ^a   Chu, Chun Che ^a   Chen, Chiung Mei ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Biomarker; Haptoglobin; Multiple sclerosis; Neuromyelitis optica

Indexed keywords

ALBUMIN; HAPTOGLOBIN;

ADULT; ALBUMIN BLOOD LEVEL; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HAPTOGLOBULIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS;

ADULT; AGED; ALZHEIMER DISEASE; FEMALE; HAPTOGLOBINS; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA;

EID: 84872230937     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.12.008     Document Type: Article

References (38)

1. Wingerchuk D.M., Hogancamp W.F., O'Brien P.C., Weinshenker B.G. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999, 53:1107-1114.
2. Wingerchuk D.M., Lennon V.A., Lucchinetti C.F., Pittock S.J., Weinshenker B.G. The spectrum of neuromyelitis optica. Lancet Neurol 2007, 6:805-815.
3. Wingerchuk D.M., Lennon V.A., Pittock S.J., Lucchinetti C.F., Weinshenker B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.
4. Lucchinetti C.F., Mandler R.N., McGavern D., et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002, 125:1450-1461.
5. Bruck W. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol 2005, 252(S5):v3-v9.
6. Lennon V.A., Wingerchuk D.M., Kryzer T.J., et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364:2106-2112.
7. Nakashima I., Fujihara K., Miyazawa I., et al. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry 2006, 77:1073-1075.
8. Matsuoka T., Matsushita T., Kawano Y., et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007, 130:1206-1223.
9. Matsushita T., Isobe N., Matsuoka T., et al. Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese. Mult Scler 2009, 15:834-847.
10. Sadrzadeh S.M., Bozorgmehr J. Haptoglobin phenotypes in health and disorders. Am J Clin Pathol 2004, 121(S1):S97-S104.
11. Bai S., Liu S., Guo X., et al. Proteome analysis of biomarkers in the cerebrospinal fluid of neuromyelitis optica patients. Mol Vis 2009, 15:1638-1648.
12. Kira J. Neuromyelitis optica and opticospinal multiple sclerosis: mechanisms and pathogenesis. Pathophysiology 2011, 18:69-79.
13. Penton-Rol G., Cervantes-Llanos M., Martinez-Sanchez G., et al. TNF-alpha and IL-10 downregulation and marked oxidative stress in Neuromyelitis Optica. J Inflamm 2009, 6:18.
14. Lutz N.W., Viola A., Malikova I., et al. Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One 2007, 2:e595.
15. Witherick J., Wilkins A., Scolding N., Kemp K. Mechanisms of oxidative damage in multiple sclerosis and a cell therapy approach to treatment. Autoimmun Dis 2010, 2011:164608.
16. Di Bona D., Scapagnini G., Candore G., et al. Immune-inflammatory responses and oxidative stress in Alzheimer's disease: therapeutic implications. Curr Pharm Des 2010, 16:684-691.
17. Polman C.H., Reingold S.C., Banwell B., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011, 69:292-302.
18. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
19. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
20. Zvi B., Levy A.P. Haptoglobin phenotypes, which one is better and when?. Clin Lab 2006, 52:29-35.
21. Lim S.K., Ferraro B., Moore K., Halliwell B. Role of haptoglobin in free hemoglobin metabolism. Redox Rep 2001, 6:219-227.
22. Tseng C.F., Lin C.C., Huang H.Y., Liu H.C., Mao S.J. Antioxidant role of human haptoglobin. Proteomics 2004, 4:2221-2228.
23. Jue D.M., Shim B.S., Kang Y.S. Inhibition of prostaglandin synthase activity of sheep seminal vesicular gland by human serum haptoglobin. Mol Cell Biochem 1983, 51:141-147.
24. Komoriya K., Hoshina K., Ohtsu A., et al. Inhibition of prostaglandin synthesizing enzymes by haptoglobin and plasma of rats with inflammation. Jpn J Pharmacol 1980, 30:899-904.
25. Javid J. Human haptoglobins. Curr Top Hematol 1978, 1:151-192.
26. Wang F., Huang W., Li A. Serum haptoglobin suppresses T-lymphocyte functions following burns. Chin Med Sci J 1996, 11:180-183.
27. Li X., Miyajima M., Mineki R., Taka H., Murayama K., Arai H. Analysis of potential diagnostic biomarkers in cerebrospinal fluid of idiopathic normal pressure hydrocephalus by proteomics. Acta Neurochir 2006, 148:859-864.
28. Conti A., Sanchez-Ruiz Y., Bachi A., et al. Proteome study of human cerebrospinal fluid following traumatic brain injury indicates fibrin(ogen) degradation products as trauma-associated markers. J Neurotrauma 2004, 21:854-863.
29. Pantoni L., Inzitari D. Abnormal penetration of haptoglobin through the blood-brain-barrier (BBB) into the cerebro-spinal fluid (CSF) in Alzheimer's disease patients. Acta Neurol Scand 1995, 91:225.
30. Chang K.H., Lyu R.K., Tseng M.Y., et al. Elevated haptoglobin concentration of cerebrospinal fluid in Guillain-Barre syndrome revealed by proteomics analysis. Proteomics Clin Appl 2007, 1:467-475.
31. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chem Acta 2001, 310:173-186.
32. Reiber H. Flow rate of cerebrospinal fluid (CSF) - a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J Neurol Sci 1994, 122:189-203.
33. Zhao X., Song S., Sun G., et al. Neuroprotective role of haptoglobin after intracerebral hemorrhage. J Neurosci 2009, 29:15819-15827.
34. Lee M.Y., Kim S.Y., Choi J.S., et al. Upregulation of haptoglobin in reactive astrocytes after transient forebrain ischemia in rats. J Cereb Blood Flow Metab 2002, 22:1176-1180.
35. Chan K.H., Zhang R., Kwan J.S., et al. Aquaporin-4 autoantibodies cause asymptomatic aquaporin-4 loss and activate astrocytes in mouse. J Neuroimmunol 2012, 245:32-38.
36. Sladkova V., Mares J., Lubenova B., et al. Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome. Neurol Res 2011, 33:415-420.
37. Roher A.E., Maarouf C.L., Sue L.I., Hu Y., Wilson J., Beach T.G. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease. Biomarkers 2009, 14:493-501.
38. Elovaara I., Palo J., Erkinjuntti T., Sulkava R. Serum and cerebrospinal fluid proteins and the blood-brain barrier in Alzheimer's disease and multi-infarct dementia. Eur Neurol 1987, 26:229-234.